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Abstract
 
Chronic inflammation containing CD8
 
1
 
 lymphocytes, neutrophils, and macrophages, and pul-
monary emphysema coexist in lungs from patients with chronic obstructive pulmonary disease.
Although this inflammatory response is believed to cause the remodeling that is seen in these
tissues, the mechanism(s) by which inflammation causes emphysema have not been defined.
Here we demonstrate that interferon 
 
g
 
 (IFN-
 
g
 
), a prominent product of CD8
 
1
 
 cells, causes
emphysema with alveolar enlargement, enhanced lung volumes, enhanced pulmonary compli-
ance, and macrophage- and neutrophil-rich inflammation when inducibly targeted, in a trans-
genic fashion, to the adult murine lung. Prominent protease and antiprotease alterations were
also noted in these mice. They included the induction and activation of matrix metalloprotein-
ase (MMP)-12 and cathepsins B, H, D, S, and L, the elaboration of MMP-9, and the selective
inhibition of secretory leukocyte proteinase inhibitor. IFN-
 
g
 
 causes emphysema and alterations
in pulmonary protease/antiprotease balance when expressed in pulmonary tissues.
Key words: chronic obstructive pulmonary disease • matrix metalloproteinase • cathepsin • 
neutrophil • secretory leukocyte proteinase inhibitor
 
Introduction
 
Chronic obstructive pulmonary disease (COPD)
 
1
 
 is a ge-
neric term covering several clinical syndromes including
emphysema and chronic bronchitis. Chronic bronchitis is
diagnosed in patients with a history of cough or sputum
production on most days for at least 3 mo for two consecu-
tive years without any other explanation (1, 2). In contrast,
emphysema is defined pathologically as a condition of the
lung characterized by abnormal permanent enlargement of
the air spaces distal to the terminal bronchiole accompa-
nied by destruction of alveolar walls (1, 2). COPD is a
pressing clinical problem. In the USA, it affects over 16
million people, accounts for 13% of hospitalizations, and is
the fourth leading cause of death (1, 3). In addition, 48
million people in the USA smoke cigarettes, the major
cause of COPD, and 3,000 people, mostly teenagers, take
up the habit each day (1). Worldwide, 1.5 million deaths
per year due to COPD are predicted in China alone over
the next half century (4). In contrast to its impressive
health care importance, COPD is the least funded disease
by the USA National Institutes of Health when adjusted
for disease burden (5).
Tissue inflammation is noted throughout the bronchial
tree and in the parenchyma of lungs from patients with
COPD. Neutrophil-, macrophage-, and/or eosinophil-rich
tissue and airway responses are seen in these locations (3, 6–
11). Lymphocyte infiltration with the enhanced accumula-
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Abbreviations used in this paper: 
 
a
 
1
 
-AT, 
 
a
 
1
 
 antitrypsin; BAL, bronchoal-
veolar lavage; CC10, clara cell 10-kD protein; COPD, chronic obstruc-
 
tive pulmonary disease; dox, doxycycline; hGH, human growth
hormone; IP-10, IFN-
 
g
 
–inducible protein 10; MMP, matrix metallopro-
teinase; Mig, monokine induced by IFN-
 
g
 
; RT, reverse transcription;
rtTA, reverse tetracycline transactivator; SLPI, secretory leukocyte pro-
teinase inhibitor; Tc1, type 1 T cytotoxic; tet-O, tetracycline operator;
TIMP, tissue inhibitor of metalloproteinase. 
1588
 
Interferon 
 
g
 
 Induction of Pulmonary Emphysema
 
tion of CD8
 
1
 
 cells is also a prominent finding (7–9, 11). It
has long been assumed that this inflammation causes the tis-
sue remodeling seen in COPD (1, 12, 13). However, the
features of this inflammatory response that cause alveolar
remodeling and the mediators that are responsible for these
changes are poorly understood.
Several lines of evidence suggest that pulmonary lym-
phocytes contribute in important ways to the pathogenesis
of the tissue remodeling responses in COPD. They include
studies demonstrating correlations between lymphocyte
counts and indices of alveolar destruction (14) and CD8
 
1
 
cell numbers and the degree of COPD airflow limitation
(8, 11). These lymphocytes are believed to be predomi-
nantly type 1 T cytotoxic (Tc1) cells that produce cyto-
kines like IFN-
 
g 
 
(6, 11, 15). Surprisingly, the ability of the
cytokines that are produced by these cells to generate the
alterations seen in pulmonary emphysema have not been
defined.
Studies of human 
 
a
 
1
 
 antitrypsin (
 
a
 
1
 
-AT) deficiency and
experiments with animal models of emphysema induced by
papain or other proteases demonstrated that emphysema
can be induced by proteolytic injury to the pulmonary ma-
trix, particularly to elastin (1, 16). This led to the protease/
antiprotease hypothesis, which is still the prevailing con-
cept in the pathogenesis of emphysema. According to this
hypothesis, the normal lung is protected by an “antipro-
tease shield” that neutralizes proteolytic enzymes that are
released into the airway or parenchyma. Emphysema is
caused by an alteration in this balance with an increase in
proteases and/or a reduction in antiproteases (1, 3). Ineffec-
tive and/or disordered repair of elastic fibers and/or col-
lagen- and oxidant-induced pulmonary injury may also
contribute to the generation of these lesions (17–19).
However, the ability of the inflammatory cells and media-
tors in COPD tissues to induce protease/antiprotease ab-
normalities that can contribute to, or activate, pulmonary
proteolysis has not been adequately investigated.
In keeping with the belief that CD8
 
1
 
 Tc1 cells play an
important role in the pathogenesis of emphysema, we hy-
pothesized that IFN-
 
g
 
 could induce the alveolar destruc-
tion characteristic of this disorder. To test this hypothesis,
we used an inducible overexpression transgenic modeling
system to target IFN-
 
g
 
 to the adult murine lung. These
studies demonstrate that IFN-
 
g
 
 causes a phenotype that
mirrors human COPD with progressive emphysema, en-
hanced lung volumes, and macrophage and neutrophilic
inflammation. They also define the prominent matrix me-
talloproteinase (MMP), cathepsin, and antiprotease alter-
ations induced by IFN-
 
g
 
 in this in vivo
 
 
 
setting.
 
Materials and Methods
 
Transgenic Mice.
 
Mice and humans are born with premature
lungs that contain large sac-like structures. Normal alveolar size
and number are acquired only after a growth and septation pro-
cess that occurs during the first month and years of life, respec-
tively (20). Thus, enlarged alveoli in adult mice or humans can be
caused by processes that alter alveolar development or processes
that destroy otherwise normal alveolar septae (1, 21, 22). The
emphysema in COPD is caused by the latter (1). Overexpression
transgenic modeling in the lung uses either the clara cell 10-kD
(CC10) or surfactant apoprotein C promoters most frequently.
Both promoters are activated in utero and, when used to drive an
appropriate transgene, have been shown to cause developmental
abnormalities (22–24). The need to differentiate development-
dependent and adult onset phenotypes confounds the use of pul-
monary overexpression transgenic modeling to study the patho-
genesis of COPD. To avoid this confounder, we used a novel,
externally regulatable, dual construct overexpression transgenic
system developed in our laboratory (22). This transgenic system
allows transgene expression to be minimized during phases of
lung development and induced after lung development has oc-
curred. The constructs used in this system have been described
previously by our laboratory (22). The CC10-rtTA-hGH con-
struct contains the CC10 promoter, the reverse tetracycline
transactivator (rtTA), and human growth hormone (hGH) in-
tronic and polyadenylation sequences (Fig. 1). The rtTA is a fu-
sion protein made up of a mutated tetracycline repressor (rtet-R)
and the herpes virus VP-16 transactivator. The tet-O-CMV-
IFN-
 
g
 
-hGH construct contains a polymeric tetracycline operator
(tet-O), minimal CMV promoter, murine IFN-
 
g
 
 cDNA, and
hGH intronic and polyadenylation signals (Fig. 1). In this system,
the CC10 promoter directs the expression of rtTA to the lung. In
the presence of doxycycline (dox), rtTA is able to bind in trans
to the tet-O, and the VP-16 transactivator activates IFN-
 
g
 
 gene
transcription. In the absence of dox, rtTA binding occurs at very
low levels and only low level gene transcription is noted. The
preparation of the CC10-rtTA construct has been described pre-
viously (22). The tet-O-CMV-IFN-
 
g
 
-hGH construct was pre-
pared by replacing the IL-11 cDNA in the construct tet-O-
CMV-hIL-11-hGH described previously by our laboratory (22)
with the murine IFN-
 
g
 
 cDNA. This construct was checked for
correct insert orientation by restriction enzyme digestion and se-
quencing. Both constructs were purified, linearized, separated by
electrophoresis through agarose, and purified as described previ-
ously (22). Transgenic mice were prepared in (CBA 
 
3
 
 C57BL/
6)F
 
2
 
 eggs by mixing and simultaneously injecting the constructs
into pronuclei as described previously (22).
 
Documentation of Transgene Status.
 
The presence or absence of
the transgenes was initially evaluated using Southern blot analysis
and later by PCR. Southern analysis was performed as described
previously using cDNA encoding murine IFN-
 
g
 
 or rtTA (22,
25). PCR for rtTA was also performed using protocols described
Figure 1. Constructs used in the generation of CC10-rtTA-IFN-g
mice. 
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by our laboratory (22, 25). PCR for the IFN-
 
g
 
–containing con-
struct was undertaken using the following primers: upper primer
5
 
9
 
-ACT CAC ATT CAG AAC CCC AAA C-3
 
9
 
, lower primer
5
 
9
 
-CGT CAG ATC GCC TGG AGA C-3
 
9
 
. The cycling condi-
tions were one cycle at 94
 
8
 
C for 4 min, 35 cycles of 94
 
8
 
C for 1
min, followed by 57
 
8
 
C for 1 min and 72
 
8
 
C for 1 min, 1 cycle at
72
 
8
 
C for 5 min, and 1 cycle at 4
 
8
 
C to end. All CC10-rtTA-IFN-
 
g
 
lineage animals were evaluated for the presence of both the rtTA-
and IFN-
 
g
 
–containing transgenic constructs.
 
Dox Water Administration.
 
CC10-rtTA-IFN-
 
g
 
 animals were
maintained on normal water until 4–6 wk of age. At that time
 
they were randomized to receive normal water or water contain-
ing dox (1.0 mg/ml) as described previously (22).
 
Bronchoalveolar Lavage and Quantification of IFN-
 
g
 
 Levels.
 
Mice were killed, the trachea was isolated by blunt dissection,
and small caliber tubing was inserted and secured in the airway.
Three volumes of 0.75 ml of PBS with 0.1% BSA were then in-
stilled and gently aspirated and pooled. Each bronchoalveolar la-
vage (BAL) fluid sample was centrifuged and the supernatants were
stored at 
 
2
 
70
 
8
 
C until used. The levels of IFN-
 
g
 
 were deter-
mined immunologically using a commercial ELISA (R&D Sys-
tems) as per the manufacturer’s instructions.
 
Table I.
 
RT-PCR Primers
 
mRNA of interest Sequences Product length
 
bp
 
Gelatinase A
(MMP-2)
 
(UP) 5
 
9
 
-TCT GCG GGT TCT CTG CGT CCT GTG C-3
 
9
 
(LO) 5
 
9
 
-GTG CCC TGG AAG CGG AAC GGA AAC T-3
 
9
 
861
Matrilysin
(MMP-7)
 
(UP) 5
 
9
 
-ACA TCA GTG GGA ACA GGC TCA G-3
 
9
 
(LO) 5
 
9
 
-ACA GTA CCG GGA ACA GAA GAG T-3
 
9
 
606
Gelatinase B
(MMP-9)
 
(UP) 5
 
9
 
-CAA AGA CCT GAA AAC CTC CAA CCT C-3
 
9
 
(LO) 5
 
9
 
-TTC TCC GTT GCC GTG CTC CGT GTA G-3
 
9
 
757
Macrophage metalloelastase 
(MMP-12)
 
(UP) 5
 
9
 
-AAG CAA CTG GGC AAC TGG ACA ACT C-3
 
9
 
 
(LO) 5
 
9
 
-TGG TGA CAG AAA GTT GAT GGT GGA C-3
 
9
 
631
Collagenase
(MMP-13)
 
(UP) 5
 
9
 
-CTT CTG GCA CAC GCT TTT CCT C-3
 
9
 
(LO) 5
 
9
 
-CGC AGC GCT CAG TCT CTT CAC C-3
 
9
 
606
MT-MMP1
(MMP-14)
 
(UP) 5
 
9
 
-GTC TCC TGC TCC CCC TGC TCA C-3
 
9
 
(LO) 59-CAT GCA CAG CCA CCA AGA AGA T-39 690
TIMP-1
(UP) 59-GCA TCT GGC ATC CTC TTG TTG-39
(LO) 59-GAC AGT GTT CAG GCT TCA GTT TTT C-39 637
TIMP-2
(UP) 59-GCA ACA GGC GTT TTG CAA TGC AGA C-39
(LO) 59-GCT TTT CAA TTG GCC ACA GGG GCT C-39 598
TIMP-3
(UP) 59-CTG GCT TGG GCT TGT CGT GCT CCT GA-39
(LO) 59-GGG AAG GAG GTG AGG TGG GGC AGG TC-39 659
TIMP-4 
(UP) 59-CAC GCC ATT TGA CTC TTC CCT-39
(LO) 59-CCA GCA GCC AGT CCG TCC AGA-39 269
Cathepsin B
(UP) 59-CTT GAT CCT TCT TTC TTG CCT GCT G-39
(LO) 59-GAA TCG TAG ACT CCA CCT GAA ACC A-39 513
Cathepsin L
(UP) 59-CTA CAC AAC GGG GAA TAC AGC AAC G-39
(LO) 59-ACT ATA GAA CTG GAG AGA CGG ATG G-39 600
Cathepsin K
(UP) 59-GGG AGA CAT GAC CAG TGA AGA AGT G-39
(LO) 59-TGC TCT CTT CAG GGC TTT CTC GTT C-39 481
Cathepsin H 
(UP) 59-CGA GCT GAC CGT GAA CGC CAT AG-39
(LO) 59-AGC TTT TTG GGG GTT GAA TCT GC-39 595
Cathepsin S
(UP) 59-GGG TTC TTG TGG TGC CTG TTG G-39
(LO) 59-CCG TAC AGG AGG GGT CAT CAT A-39 425
SLPI
(UP) 59-CTG GAC TGT GGA AGG AGG CAA AAA TG-39
(LO) 59-AGT AGT TTC CAG AGC ACA CCG AGC AC-39 398
a1-AT
(UP) 59-TGC CCA TGA TGA CCC TCT C-39
(LO) 59-TGG GGC TCT GAG TGT GTT CT-39 498
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Lung Volume and Compliance Assessment. The animals were
anesthetized, the trachea was cannulated, and the lungs were ven-
tilated with 100% O2 via a “T” piece attachment. The tracheal
cannula was then clamped and oxygen was absorbed in the face
of ongoing pulmonary perfusion. At the end of this degassing, the
lungs and heart were removed en bloc and inflated to 25 cm
pressure with PBS. Static compliance was calculated as the
change in volume divided by the change in pressure.
Histologic Analysis. Animals were killed, a median sternotomy
was performed, and right heart perfusion was accomplished with
calcium and magnesium–free PBS to clear the pulmonary intra-
vascular space. The heart and lungs were then removed en bloc,
inflated to 25 cm with neutral-buffered 10% formalin, fixed over-
night in 10% formalin, embedded in paraffin, sectioned at 5 mm,
and stained. Hematoxylin and eosin, Congo red, and periodic
acid-Schiff with diastase (D-PAS) stains were performed in the
Research Histology Laboratory of the Department of Pathology
at Yale University School of Medicine.
mRNA Analysis. mRNA levels were assessed using Northern
blot and reverse transcription (RT)-PCR as described previously
by our laboratories (25, 26). In these experiments, total cellular
RNA from lungs or a variety of other mouse tissues were ob-
tained using Trizol reagent (GIBCO BRL) as per the manufac-
turer’s instructions. When Northern blots were being performed,
the RNA was fractionated by formaldehyde–agarose gel electro-
phoresis, transferred to a nylon membrane, and probed with 32P-
labeled cDNA encoding the moiety of interest. The cDNA
probes were generated using RT-PCR with the primers in Table
I and whole lung RNA from CC10–IL-13 mice (25). All cDNA
was sequenced before utilization. Equity of sample loading and
the efficacy of transfer were assessed by stripping and reprobing
the membrane with cDNA encoding b-actin.
In the RT-PCR assays, RNA samples were obtained and re-
verse transcribed. For the proteases and antiproteases, gene-spe-
cific primers (Table I) were used to amplify selected regions of
each target moiety. When IFN-g mRNA was being assessed, an
upper primer in IFN-g and a lower primer in hGH were used
(upper GAGGAACTGGCAAAAGGATG; lower GATTT-
TAGGGGCGCTACCT). This yielded a 418-bp reaction prod-
uct. To verify that equal amounts of undegraded RNA were
added in each RT-PCR reaction, b-actin was used as an internal
standard. PCR products were quantitated after 20, 25, and 30 cy-
cles of amplification. Amplified PCR products were detected us-
ing ethidium bromide gel electrophoresis, quantitated electroni-
cally, and confirmed by nucleotide sequencing.
Western Blot Analysis. Western blot analysis of BAL fluid was
performed using antibodies to MMP-12 (27) as described previ-
ously by our laboratories (26).
Zymography. Gelatin and casein zymography were performed
using BAL fluid as described previously by our laboratories (28).
Active Site Probe Analysis of Cysteine Proteases. Active site
probe analyses were performed as described previously by our
laboratories (29). Lung lysates or cell-free BAL, normalized to to-
tal protein, were incubated with an 125I-JPM analogue of E-64
and resolved by SDS-PAGE and autoradiography.
Morphometric Analysis. Alveolar size was estimated from the
mean cord length of the airspace as described previously by our
laboratories (30). This measurement is similar to the mean linear
intercept, a standard measure of air space size, but has the advan-
tage that it is independent of alveolar septal thickness. Sections
were prepared as described above. To obtain images at random
for analysis, each glass slide was placed on a printed rectangular
grid and a series of dots was placed on the coverglass at the inter-
section of the grid lines, i.e., at z1-mm intervals. Fields as close
as possible to each dot were acquired by systematically scanning
at 2-mm intervals. Fields containing identifiable artifacts or non-
alveolated structures such as bronchovascular bundles or pleura
were discarded.
A minimum of 10 fields from each mouse lung were acquired
into a Macintosh computer through a framegrabber board. Im-
ages were acquired in 8 bit grayscale at a final magnification of
1.5 pixels/mm. The images were analyzed on a Macintosh G3
computer using the public domain NIH Image program written
by Wayne Rasband at the National Institutes of Health (available
at http://rsb.info.nih.gov/nih-image using a custom written
macro available from the web site). Images were manually thresh-
olded, then smoothed and inverted. The image was then subject
to sequential logical image match “and” operations with a hori-
zontal and then vertical grid. At least 200 measurements per field
were made in transgene-positive animals and 400 measurements
per field were made in the transgene-negative animals. The
length of the lines overlying air space was averaged as the mean
chord length. At least four animals were studied at each time
point in the presence and absence of dox water. Chord length in-
creases with alveolar enlargement.
Statistical Analysis and Data Presentation. Values are expressed
as means 6 SEM. As appropriate, group means were compared
by analysis of variance with Scheffe’s procedure post hoc analysis
or with the Student’s two-tailed unpaired t test using the Stat-
View software for the Macintosh (Abacus Concepts, Inc.). The
illustrated effects of IFN-g on the levels of mRNA encoding
proteases or antiproteases are representative of the results ob-
tained in evaluations of a minimum of six separate animals.
Results
Generation of Transgenic Mice. To characterize the ef-
fects of IFN-g in the adult lung, we used a novel, exter-
nally regulatable, dual construct overexpression transgenic
system developed in our laboratory (22). The constructs re-
quired for these transgenics were prepared, purified, and si-
multaneously microinjected. Tail biopsies were obtained
Figure 2. Southern blot analysis of DNA from potential founder mice.
The requisite constructs were prepared and microinjected as described in
Materials and Methods. Tail biopsies were obtained from potential
founder animals, DNA was extracted, and the presence of the rtTA- and
IFN-g–containing constructs was evaluated by Southern blot analysis.
The transgenes in three dual transgene-positive founder mice and a trans-
gene-negative littermate control are compared with copy number con-
trols of the CC10-rtTA-hGH and tet-O-CMV-IFN-g-hGH constructs.1591 Wang et al.
from potential founder animals, DNA was isolated, and the
presence or absence of the IFN-g and rtTA transgenic se-
quences was determined via Southern blot analysis and
PCR. Three dual-positive founder animals were obtained
(Fig. 2). They were subsequently backcrossed with
C57BL/6 mice to generate transgene-negative and trans-
gene-positive progeny.
Regulation of IFN-g Production. Transgene-negative and
transgene-positive mice were kept on normal water until
they were 4–6 wk of age. They were then randomized to
normal water or water with dox. In the absence of dox ad-
ministration, BAL IFN-g levels were ,70 pg/ml. As illus-
trated in Fig. 3, dox administration caused a significant in-
crease in BAL IFN-g. This increase was noted within 24 h
of dox administration, persisted for extended intervals, and
returned to baseline values within 4 d of removing the dox
from the animal’s drinking water. The different transgenic
lines had BAL IFN-g levels between 370 and 1,200 pg/ml
after 1 wk of dox administration.
To determine if the IFN-g that was produced in our
transgenic animals was bioactive, studies were undertaken
to determine if the IFN-g–regulated genes IFN-g–induc-
ible protein 10 (IP-10) and monokine induced by IFN-g
(Mig) were stimulated after dox administration. mRNA
encoding either gene could not be appreciated in trans-
gene-negative mice on normal water or dox water (Fig. 4).
In contrast, mRNA encoding IP-10 and Mig was weakly
detected in transgene-positive mice on normal water, and
impressive induction of both genes could be appreciated af-
ter dox administration (Fig. 4). These studies clearly dem-
onstrate that the IFN-g that is produced in the lungs of
these transgenic mice is bioactive.
Organ Specificity of Transgene Expression. To determine
if IFN-g was appropriately targeted to the lung, RNA was
obtained from the lungs and a variety of other tissues from
Figure 3. Kinetics of dox regulation of IFN-g in CC10-rtTA-IFN-g
mice. The kinetics of dox induction of IFN-g are illustrated in the top
panel. In these experiments, BAL was performed on 1-mo-old dual trans-
gene-positive animals (0 d) and identical animals after the noted intervals
of dox water exposure. In the bottom panel, the kinetics of IFN-g elimi-
nation are illustrated. In these experiments, 1-mo-old dual transgene-pos-
itive animals were placed on dox for 1 wk and then placed back on nor-
mal water. The levels of BAL IFN-g were evaluated at the time the
animals went from normal water to dox water (time 0) and at intervals
thereafter. The noted values represent the means 6 SEM of a minimum
of four animals at each time point.
Figure 4. Demonstration that BAL IFN-g is bioactive. 1-mo-old
transgene-negative and transgene-positive animals were randomized to
receive normal water or dox water for up to 14 d. The levels of mRNA
encoding IP-10 (A) and Mig (B) were evaluated via Northern blot analy-
sis. Ethidium bromide–stained gels illustrating 28 S and 18 S ribosomal
RNA are illustrated below each gel, demonstrating equity of sample load-
ing. Similar results were obtained in three separate experiments.
Figure 5. Representative experiment (of n 5 4) illustrating the organ
specificity of IFN-g expression. RNA was isolated from the lungs and a
variety of other organs from 6-wk-old dual transgene-positive mice that
had received dox water for 2 wk. The levels of mRNA encoding IFN-g
were evaluated by RT-PCR as described in Materials and Methods.1592 Interferon g Induction of Pulmonary Emphysema
transgene-positive mice that had received dox water for 2
wk. IFN-g mRNA was then evaluated via RT-PCR anal-
ysis. Impressive levels of IFN-g mRNA could be appreci-
ated in lungs from transgene-positive mice on dox water.
In contrast, transgene-induced IFN-g mRNA was not
noted and histologic abnormalities were not appreciated in
a variety of visceral tissues from transgene-positive animals
(Fig. 5, and data not shown). This demonstrates that our
CC10-driven transgenic system, as described previously by
this laboratory and others (22, 23, 31), selectively targets
IFN-g to the lungs of these transgenic animals.
Effect of IFN-g on BAL Cellularity. Dual transgene-pos-
itive and transgene-negative mice were kept on normal
water until they were 4–6 wk of age. They were then
placed on normal water or water with dox and maintained
on this regimen for an additional month. At the end of this
interval they were killed and BAL cellularity was evaluated.
The cell recovery and cellular differentials of BAL fluids
from transgene-negative mice on normal and dox water
were almost identical (Table II). In contrast, IFN-g in-
creased BAL cell recovery. Modest increases in cellularity
were seen in transgene-positive mice on normal water and
impressive increases were seen after dox induction. At this
time point, BAL fluids from dual transgene-positive mice
on dox water had z9- and 11.5-fold more cells than the
BAL fluids from transgene-negative animals on normal and
dox water, respectively (Table II; P , 0.005). The BAL
fluids from the transgene-positive mice also had an in-
creased percentage and recovery of neutrophils and lym-
phocytes and an exaggerated number of macrophages com-
pared with transgene-negative controls (P , 0.05 for all
comparisons; Table II). Abnormalities in eosinophil recov-
ery were not noted. These studies demonstrate that IFN-g
increases the pulmonary accumulation of macrophages,
lymphocytes, and neutrophils.
Histologic, Physiologic, and Structural Effects of IFN-g. In-
flammation and mucus metaplasia were not seen in the he-
matoxylin and eosin and periodic acid-Schiff stains of the
lungs from transgene-negative mice on normal water. Sim-
ilarly, mucus alterations were not noted in the histologic
sections from the transgene-positive mice on normal or
dox water (data not shown). In contrast, inflammation was
noted in lungs from transgene-positive animals. This re-
Table II. IFN-g Regulation of BAL Cellularity
Differential
Transgene
status* Recovery M L N E
3104 %%%%
2 4.2 6 0.6 97 6 0.6 2.2 6 0.4 0.4 6 0.3 0.3 6 0.2
2dox 3.3 6 0.1 97  6  2.0 3.0  6  1.2 0.3  6  0.1 0.1  6  0.01
1 10 6 4.3 56 6 5.1 28 6 5.0 15 6 3.0 1 6 0.1
1dox 38.1 6 7.8‡ 54 6 3.6§ 31 6 3.5§ 15 6 1.7§ 0.1 6 0.01
*4–6-wk-old transgene-negative (2) and dual transgene-positive (1)
mice were placed on normal water (2dox) or dox water (1dox) for 1
mo. BAL was then performed and cell recovery and differentials were
evaluated. The noted values represent the mean 6 SEM of a minimum
of three animals.
‡P , 0.01 versus transgene-negative mice and transgene-positive mice
on normal water.
§P , 0.05 versus transgene-negative mice.
Figure 6. Inflammation in
transgenic mice. Transgene-neg-
ative, Tg (2), and dual trans-
gene-positive, Tg (1), mice at 1
mo of age were randomized to
normal water, dox (2), or dox
water, dox (1), for 3 mo. The
lungs were then removed, fixed
to pressure, sectioned, stained
(hematoxylin and eosin), and
photographed (original magnifi-
cation: 3100). These photomi-
crographs are representative of
the results obtained in a mini-
mum of 10 experiments evaluat-
ing the histology of transgene-
positive and transgene-negative
mice on normal water or dox
water.1593 Wang et al.
sponse contained increased numbers of mononuclear cells
and rare neutrophils. It was mild and patchy and, when
seen, was noted in peribronchiolar and alveolar parenchy-
mal locations. Abnormalities of the airways in these loca-
tions were not appreciated. This response could be appreci-
ated in transgene-positive mice that had received at least 1
mo of dox water but was not consistently detected in trans-
gene-positive mice on normal water (Fig. 6, and data not
shown).
The alveoli in lungs from transgene-negative mice on
normal water and dox water were normal in size and ap-
pearance (Fig. 7). In contrast, alveolar enlargement was
noted in the dual transgene-positive animals. A modest in-
crease in alveolar size was seen in 1-mo-old, dual trans-
gene-positive mice that had received normal water (Fig. 7).
Dox-induced IFN-g caused a further increase in alveolar
size. This effect was dose and time dependent. It was most
prominent in transgenic lines that produced high levels of
IFN-g after dox administration. In these mice, a marginal
increase in alveolar size was noted after 4–6 wk and impres-
sive emphysema was noted after 3 mo of dox administra-
tion (Fig. 7, and data not shown). This emphysema mani-
fest as histologic (Fig. 7) and morphometrically obvious
(Fig. 8) alveolar enlargement with loss of the orderly ap-
pearance of the acinus (32). The morphometric studies re-
vealed a .100% increase in chord length. This is signifi-
Figure 7. Alveolar histology in transgenic
mice. Transgene-negative, Tg (2), and dual
transgene-positive, Tg (1), mice at 1 mo of
age were randomized to normal water, dox
(2), or dox water, dox (1), for 3 mo. The
lungs were then removed, fixed to pressure,
sectioned, stained (hematoxylin and eosin),
and photographed (original magnification:
325). Mild alveolar enlargement is seen in
the transgene-positive animals on normal
water and further alveolar enlargement is
seen in transgene-positive animals receiving
dox. These photomicrographs are represen-
tative of the results obtained in a minimum
of 10 experiments evaluating the alveolar
histology of transgene-positive and trans-
gene-negative mice on normal water and
dox water.
Figure 8. Morphometric parameters of alveolar size in CC10-rtTA-
IFN-g mice. Transgene-negative (Neg) and transgene-positive (Pos)
mice were randomized to normal water (2Dox) or dox water (1Dox) at
1 mo of age and maintained on this regimen for 3 mo. Lungs were then
removed, fixed to pressure, stained, and alveolar chord length was quanti-
tated (*P , 0.01 versus all other conditions). The noted values represent
the mean 6 SEM of a minimum of five animals.
Table III. Effects of IFN-g on Lung Volume and
Static Compliance
Transgene
status* Dox
Lung
volume Compliance
ml ml/cm
22 0.9 6 0.001 0.036 6 0.001
21 0.9 6 0.04 0.036 6 0.003
12 1.5 6 0.13 0.06 6 0.001
11 2.4 6 0.04‡ 0.096 6 0.05‡
*1-mo-old transgene-negative (2) and dual transgene-positive (1)
mice were randomized to normal water or dox water for 3 mo. Lung
volumes were then assessed via volume displacement after fixation to
pressure (25 cm). The noted values represent the mean 6 SEM of eval-
uations on a minimum of four mice for each group.
‡P , 0.05 versus transgene-positive mice on normal water and trans-
gene-negative mice on normal or dox water.1594 Interferon g Induction of Pulmonary Emphysema
cantly greater than the 25–30% increase in morphometric
parameters of alveolar size that we noted in similar mice
exposed to cigarette smoke for 6 mo (27).
Enhanced lung volumes and increased pulmonary com-
pliance are characteristic features of human emphysema (1).
To determine if this murine model recapitulates these im-
portant clinical features of COPD, 1-mo-old transgene-
negative and transgene-positive mice were randomized to
normal water and dox water for up to 3 mo. Lung volumes
were then assessed after pressure fixation. As can be seen in
Table III and Fig. 9, dox induction of IFN-g caused a pro-
gressive increase in lung volume and an impressive increase
in pulmonary compliance compared with dual transgene-
positive animals on normal water or transgene-negative
animals on normal or dox water. When viewed in combi-
nation, these studies demonstrate that IFN-g causes em-
physema with lung volume enlargement and enhanced pul-
monary compliance analogous to that seen in human
COPD.
Effect of IFN-g on MMPs. To begin to define the
mechanism(s) of IFN-g–induced alveolar septal destruc-
tion, we compared the levels of mRNA encoding a variety
of COPD-relevant MMPs in transgene-negative and trans-
gene-positive mice that had been randomized to receive
normal water or dox water at 1 mo of age and maintained
on this regimen for up to 12 wk. These studies demon-
strated that IFN-g is a potent stimulator of MMP-12
mRNA accumulation (Fig. 10). This effect could be appre-
ciated after as little as 1 wk of dox administration and was
readily apparent throughout the 3-mo induction interval
(data now shown). MMP-2, MMP-9, and MMP-14
mRNA were not induced in these animals. Western blot
analysis confirmed the induction of MMP-12 (Fig. 11).
Zymography also demonstrated IFN-g–induced BAL moi-
eties that comigrated with the unprocessed and/or fully
processed forms of MMP-12 (Fig. 11). Interestingly, BAL
moieties that comigrated with MMP-9 moieties were also
appreciated (Fig. 11). The activities in these bands were in-
Figure 9. Size of lungs from
transgenic mice. 1-mo-old trans-
gene-negative and transgene-
positive mice were randomized
to receive normal water (Dox
2) or dox water (Dox 1) for 3
mo. Their lungs were then re-
moved, fixed to pressure, and
photographed. The lungs pic-
tured are representative of the
results obtained in five separate
experiments.
Figure 10. Effect of IFN-g on
MMP mRNA. 1-mo-old trans-
gene-negative and dual trans-
gene-positive CC10-rtTA-IFN-g
mice and their littermate con-
trols were randomized to normal
water (2) or dox water (1) for 1
mo. RT-PCR was used to com-
pare the levels of mRNA encod-
ing a variety of MMPs in lungs
from these animals. The levels of
mRNA encoding MMPs are
compared with the levels of
mRNA encoding b-actin.
Figure 11. Effect of IFN-g on MMP protein. 1-mo-old transgene
(Tg)-negative and dual transgene-positive CC10-rtTA-IFN-g mice and
their littermate controls were randomized to normal water (2) or dox
water (1) for 1 mo. Western blot analysis (A), casein zymography (B),
and gelatin zymography (C) were used to demonstrate the presence of
MMPs in BAL fluids from these animals.1595 Wang et al.
hibited by EDTA, which establishes them as metallopro-
teinases. Thus, IFN-g is a potent and selective inducer of
MMP-12 and stimulates the release of MMP-9 in vivo.
IFN-g Regulation of Cysteine Proteinases. Studies were
next undertaken to determine if cysteine proteinases were
induced by IFN-g in our transgenic system. This was done
by comparing the levels of mRNA encoding a variety of
airway-relevant cysteine proteinases in lungs from dual
transgene-positive animals and transgene-negative litter-
mate controls that had been randomized to normal water
or dox water at 1 mo of age and maintained on this regi-
men for 4 wk. RT-PCR and Northern blot evaluations
demonstrated that IFN-g increased the levels of mRNA
encoding cathepsins D, H, S, and B. Stimulation of
mRNA encoding cathepsins K and L could not be appreci-
ated (Fig. 12, and data not shown). Active site probe analy-
sis, which identifies bioactive cathepsin moieties (29), also
demonstrated increased levels of cathepsins H, S, B, and L
in lung lysates and free cathepsin B and S in BAL fluids
(Fig. 13, and data not shown). Thus, IFN-g is a potent in
vivo inducer of cysteine proteinases in the lung.
IFN-g Regulation of Antiproteases in the Lung. To fully
understand the protease/antiprotease balance in the lungs
of IFN-g transgenic mice, the levels of expression of lung-
relevant antiproteases were also evaluated. Studies using
RT-PCR and Northern blot analysis demonstrated that
IFN-g did not alter the expression of tissue inhibitor of
metalloproteinase (TIMP)-1, TIMP-2, TIMP-3, or a1-
AT. However, IFN-g did significantly inhibit the expres-
sion of secretory leukocyte proteinase inhibitor (SLPI; Fig.
14, and data not shown).
Discussion
Chronic inflammation and structural remodeling coexist
and are believed to be linked in a cause and effect fashion
in COPD tissues (7, 12–14). Surprisingly, virtually nothing
is known about the mechanism(s) by which COPD inflam-
mation causes these structural alterations. We hypothesized
that selected mediators of COPD tissue inflammation could
directly induce pulmonary emphysema. To test this hy-
pothesis, we used inducible overexpression transgenic
modeling to target COPD-relevant inflammatory media-
tors to the adult murine lung. IFN-g was chosen for these
investigations. This choice was based on prior studies dem-
onstrating that CD81 lymphocyte infiltration is a promi-
nent feature of the pathology of COPD, that lymphocytic
number correlates with tissue destruction and airflow limi-
tation in this disorder, and that CD81 cells are potent pro-
ducers of IFN-g, and the belief that these cells elaborate
type I cytokines (6–8, 11, 14, 15). These studies demon-
strate that the overexpression of IFN-g causes a phenotype
that mirrors human COPD with prominent emphysema,
enlarged lungs, enhanced pulmonary compliance, and a
mixed tissue and BAL inflammatory response containing
increased numbers of macrophages, lymphocytes, and neu-
trophils. They also demonstrate that IFN-g shifts pulmo-
nary protease/antiprotease balance in a proteolytic direc-
tion via inducing MMP-12 and a variety of cathepsins
Figure 12. Effect of IFN-g on respi-
ratory cathepsin mRNA. RT-PCR
analysis was used to compare the levels
of mRNA encoding the noted cathep-
sins in lung lysates from 2-mo-old trans-
gene (Tg)-negative and transgene-posi-
tive CC10-rtTA-IFN-g mice that had
received normal water or dox water for
the 4-wk interval before evaluation.
Figure 13. Effect of IFN-g on cathepsin proteins (B, H, S, and L).
1-mo-old transgene-negative and dual transgene-positive mice were ran-
domized to normal water or dox water. 4 wk later, active site probe anal-
ysis was used to characterize the levels of cathepsins in lysates from the
lungs from these animals.
Figure 14. Effect of IFN-g on
respiratory antiproteases. RT-
PCR was used to compare the
levels of mRNA encoding respi-
ratory-relevant antiproteases in
2-mo-old transgene-negative
and transgene-positive CC10-
rtTA-IFN-g mice that received
either normal water (2) or dox
water (1) from 1–2 mo of age.
The lack of effect of IFN-g on
TIMP-1, -2, and -3, and a1-AT,
and the ability of IFN-g to in-
hibit SLPI can be appreciated.1596 Interferon g Induction of Pulmonary Emphysema
while inhibiting SLPI. These are the first studies to demon-
strate that IFN-g, or any type I cytokine, can cause
COPD-relevant pulmonary structural remodeling and tis-
sue inflammation. They are also the first studies to define
the in vivo, protease/antiprotease alterations induced by
IFN-g in the lung. When viewed in combination, these
studies demonstrate that IFN-g is an important regulator of
pulmonary protease/antiprotease balance and suggest that
IFN-g, and/or the pathways it activates, may contribute to
the pathogenesis of pulmonary emphysema.
The type of immune response that develops in response
to a foreign antigen can be attributed, at least in part, to the
heterogeneity of responding T cell populations (33). Type I
and type II polarized inflammatory responses represent
contrasting and, at times, mutually antagonistic, responses
of an organism to immunogenic insult. The specialized cy-
tokine profiles of type 1 and type 2 lymphocytes that medi-
ate these responses (for a review, see reference 34) are
major determinants of the outcomes of many immune re-
sponses including autoimmune, allergic, and infectious dis-
eases. This is nicely illustrated in our current concept of
asthma pathogenesis, which suggests that CD41 Th2-dom-
inated inflammation is the cornerstone of this disorder (34).
In contrast to asthma, CD81 cells are the major lympho-
cytes in tissues from patients with COPD with airflow ob-
struction (8, 11). Until recently, CD81 cells were consid-
ered a uniform class whose major function was MHC class
I–restricted (cytotoxic) lysis of infected or altered host cells,
at least in part, via the production of IFN-g (11). It is now
known that excessive or inappropriate activation of CD81
cells can also induce pathologic changes in lung tissues (35)
and that CD81 cells have a broader cytokine profile than
suspected previously (36). Our studies demonstrate that
IFN-g causes emphysema while inducing and activating a
variety of pulmonary proteolytic pathways. This observa-
tion suggests that emphysema may be a Tc1/IFN-g–medi-
ated disorder. However, this speculation must be viewed
with caution because sputum and tissue eosinophilia are
also seen in some patients with this disorder (10, 37). This
raises the possibility that type 2 cytokine mediators may
also contribute to disease pathogenesis in some individuals.
IL-13 is an attractive candidate mediator of this response
because it induces tissue eosinophilia (25) and causes em-
physema when targeted to the adult murine lung (37a). In-
terestingly, IL-13 can be produced by Tc1 as well as Tc2
cells (38). Thus, COPD, in these individuals, could be a
mixed Tc1/Tc2 disorder or a Tc1-dominant disease in
which IL-13 is produced and tissue eosinophilia is gener-
ated by Tc1 cells. These observations and our studies allow
us, for the first time, to begin to view the spectrum of clin-
ical presentations of COPD from the perspective of the
Tc1/Tc2 cytokine paradigm. However, additional experi-
mentation will be required to define the applicability of this
paradigm to this complex disorder(s).
The recruitment and activation of neutrophils in the
lung has been considered for years to be a major contribu-
tor to the pathogenesis of emphysema (16, 39). This is
based on studies demonstrating neutrophil accumulation in
BAL fluids and, to a lesser extent, tissues from patients with
COPD (1, 6, 7, 16), correlations between neutrophil num-
ber and airflow obstruction in severe COPD (7), and the
potent tissue-destructive and mucus-enhancing effects of
neutrophil-derived serine proteases (13, 40, 41). Macro-
phage-derived leukotriene (LT)B4 (42), epithelial-derived
IL-8 (16, 43), and cigarette-derived nicotine (44) have been
postulated to contribute to the generation of neutrophilia
in COPD. Repetitive endotoxin exposure has also been
shown to produce pulmonary neutrophilia and emphysema
in some animal modeling systems (45). Our studies demon-
strate that the targeted pulmonary expression of IFN-g in-
creases BAL neutrophils to levels comparable to those seen
in human COPD. Several laboratories have demonstrated
that tissue neutrophilia can be induced in the lung via the
passive transfer and activation of polarized type I cells (46)
and that IFN-g augments tissue responses to endotoxin
(47). These findings suggest that CD81 cell IFN-g is re-
sponsible, at least in part, for the recruitment and activation
of neutrophils in the lungs of cigarette smokers and that the
structural events that ensue are mediated, in part, by the
consequences of these cells in alveolar structures. They also
raise the possibility that IFN-g–induced exaggerated re-
sponses to ambient levels of environmental endotoxin may
contribute to this response. These hypotheses link, for the
first time, the lymphocyte and neutrophil abnormalities in
COPD.
To gain insight into the mechanisms of IFN-g–induced
pulmonary proteolysis, we determined if IFN-g altered the
levels of expression of lung-relevant MMPs. These studies
demonstrate, for the first time, that IFN-g is a potent and
selective stimulator of MMP-12 in vivo. This observation
compliments prior studies from our laboratories that dem-
onstrated that MMP-12 is essential for cigarette smoke–
induced inflammation and emphysema in the murine lung
(27) and is expressed in an exaggerated fashion in alveolar
macrophages from smokers and patients with emphysema
(48). Our studies also demonstrate, for the first time, that
IFN-g stimulates BAL MMP-9 protein accumulation and
that these protein alterations are not associated with simul-
taneous increases in MMP-9 mRNA. The dissociation be-
tween the effects of IFN-g on mRNA and protein suggests
that IFN-g increases MMP-9 elaboration by acting on cells
with pools of preformed enzyme such as the neutrophil
(49). In accord with these observations, exaggerated levels
of MMP-9 have been found in BAL fluids from patients
with COPD and the neutrophil has been shown to be the
major source of this enzyme in this setting (50). When
viewed in combination, these observations suggest that cig-
arette smoke may induce MMP-12 and stimulate MMP-9
elaboration via the induction of IFN-g and that the ability
of these MMPs to degrade elastin, basement membrane
components (fibronectin, laminin, entactin, vitronectin,
and type IV collagen), and nonbasement membrane com-
ponents (converting plasminogen to angiostatin and acti-
vating latent TNF [17, 51]) contributes to the pathogenesis
of IFN-g–mediated lesions. However, it is important to
point out that induction and exaggerated expression of the1597 Wang et al.
MMP-2–MMP-14–TIMP-2 complex and mucus metapla-
sia are also seen in human COPD tissues (1, 52) but not in
our IFN-g–treated murine lungs. These observations sug-
gest that IFN-g–independent mechanisms also exist and
contribute to the pathogenesis of COPD.
Although cysteine proteases play a major role in lysoso-
mal protein degradation, they also participate in extracellu-
lar biologic responses (53). Several investigators have sug-
gested that cysteine proteinases play important roles in the
pathogenesis of emphysema (12, 53–55). This includes
studies that demonstrate increased levels of cathepsin L pro-
tein, mRNA, and bioactivity in BAL cells and fluids from
smokers versus nonsmokers (54, 55). However, the patho-
genetic importance of individual cathepsin moieties in ani-
mal models of COPD have not been established, their roles
in human COPD have not been defined, and the mecha-
nisms of cysteine proteinase induction in COPD have not
been elucidated. Our studies demonstrate, for the first time,
that IFN-g is a potent in vivo stimulator of the production
and activation of a variety of pulmonary cathepsins includ-
ing cathepsins D, H, S, B, and L. The elastolytic, col-
lagenolytic, and gelatin degrading properties of these en-
zymes make them tempting candidates for the proteolysis
that is believed to underlie pulmonary emphysema. They
also raise the possibility that IFN-g, or the proteolytic
pathways it activates, plays important roles in other pulmo-
nary proteolytic responses. This could be particularly im-
portant in diseases characterized by type 1 cytokine–domi-
nated tissue inflammation and tissue destruction or
remodeling, including pulmonary infections such as tuber-
culosis and pulmonary inflammatory disorders such as ad-
vanced sarcoidosis.
To fully understand the protease/antiprotease alterations
that lead to emphysema, we also characterized the levels of
expression of a variety of important antiproteases in the
lungs of IFN-g–overexpressing animals. Significant alter-
ations in TIMP-1, -2, and -3 and a1-AT were not noted.
Interestingly, significant inhibition of SLPI was readily ap-
preciated. SLPI is a 12-kD protein produced at epithelial
surfaces. It is a potent inhibitor of elastase and serine pro-
teinases, modulates tissue inflammation, and functions as a
defensin-like antibiotic (56). It is thus reasonable to specu-
late that IFN-g inhibition of pulmonary SLPI can contrib-
ute to the proteolysis, chronic inflammation, and recurrent
infections that are seen in patients with COPD.
Our studies demonstrate that the transgenic overexpres-
sion of IFN-g in the adult murine lung causes a phenotype
compatible with human emphysema. However, it is im-
portant to point out that exaggerated IFN-g production
and/or CD 81 cell accumulation are also noted in a variety
of other pulmonary disorders, including sarcoidosis, tuber-
culosis, obliterative bronchiolitis, allograft rejection, pul-
monary fibrosis, and HIV and other viral infections (57–
65). In accord with our hypothesis that chronic IFN-g
production activates pulmonary proteolytic pathways, em-
physema is seen in patients with HIV infection (64) and
pulmonary cavitation is seen in patients with advanced tu-
berculosis and sarcoidosis. The lack of emphysema or overt
pulmonary destruction in the other disorders may be due
to differences in the site(s), timing, and/or magnitude of
IFN-g production in the different disorders. Alternatively,
it is well known that cytokine effector functions are
context dependent with the same cytokine having different
effects in different organs and different effects in the same
organ, depending on the other cells and or mediators that
are present in the local microenvironment. In addition, it is
increasingly appreciated that host genetic background and
polymorphisms in crucial disease-modifying genes also reg-
ulate the phenotypic features that are induced by inflamma-
tion-regulating mediators. Thus, as yet unidentified fea-
tures of the responses in these disorders may also serve to
exaggerate or inhibit IFN-g–induced pulmonary proteoly-
sis. Additional investigation will be required to define the
conditions under which IFN-g induces emphysema and
pulmonary proteolysis and the responses that augment and/
or ameliorate these responses.
In summary, these studies demonstrate that the targeted
expression of IFN-g in the adult lung causes emphysema
and a macrophage-, lymphocyte-, and neutrophil-rich re-
sponse that mirrors, in many ways, the lesions seen in hu-
man COPD. They also demonstrate that this emphysema-
tous response is associated with the induction and
activation of MMP-12 and cathepsins B, H, S, D, and L,
the enhanced elaboration of MMP-9, and the inhibition of
SLPI. They suggest that IFN-g may play an important role
in the pathogenesis of pulmonary emphysema and provide
the rationale for investigations of the role(s) of IFN-g in
the pathogenesis of human COPD.
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